Primary Immunodeficiency Clinical Trials

42 clinical trials for Primary Immunodeficiency across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders — RECRUITING
• NIAID Centralized Sequencing Protocol — RECRUITING
• Metabolic Profiling of Immune Responses in Immune-mediated Diseases — RECRUITING
• Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies — RECRUITING
• Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC — RECRUITING
• Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT — RECRUITING · PHASE2
• Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation — RECRUITING
• Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency — RECRUITING · NA
• An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of leniolisib for immune dysregulation in patients with primary immunodeficiency — TERMINATED · PHASE2
• An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) — COMPLETED · PHASE4
• Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France — COMPLETED · NA
• Quality of Life Among Children With Inborn Error of Immunity — NOT_YET_RECRUITING
• Severe Immune Cytopenia Registry Www.Sic-reg.Org — COMPLETED
• Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant — COMPLETED · PHASE1
• A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency — COMPLETED · PHASE4
• Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant — TERMINATED · PHASE1
• Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study — TERMINATED · PHASE1
• Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO) — COMPLETED
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency — COMPLETED · PHASE3
• What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)? — COMPLETED
• Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% — COMPLETED · PHASE3
• Systematic Screening for Primary Immunodeficiencies in Patients Hospitalized for Severe Infections in Intensive Care. — OTHER
• Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) — COMPLETED · PHASE3
• COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency — OTHER
• CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL — COMPLETED · PHASE3
• Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency — COMPLETED · PHASE3
• Minipooled-IVIG in Primary Immunodeficiency Disease — COMPLETED · NA
• Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency — WITHDRAWN · PHASE3
• Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) — COMPLETED · PHASE4
• Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency — COMPLETED · PHASE3
• IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia — COMPLETED · PHASE4
• A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push — COMPLETED · PHASE4
• Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps — COMPLETED · PHASE4
• The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations — COMPLETED
• Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study — COMPLETED
• Diagnostic Immunization With Rabies Vaccine in Patients With PID — OTHER · PHASE4
• ASIS for GAMMAGARD in Primary Immunodeficiency — OTHER · PHASE1
• Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml — COMPLETED · PHASE3
• Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency — COMPLETED · PHASE4
• Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study) — COMPLETED · PHASE3
• Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. — COMPLETED · PHASE3
• Subcutaneous Ig NextGen 16% in PID Patients — COMPLETED · PHASE3

Refine this search